Active Biotech AB Interim report January - March 2
Post# of 301275
(Total Views: 103)
Posted On: 05/17/2018 10:15:16 AM
Active Biotech AB Interim report January - March 2018
First quarter in brief
- Decision on new share issue with preferential rights for shareholders taken at Extraordinary General Meeting on March 19, 2018
- Patent application for tasquinimod for the treatment of multiple myeloma approved in the US
- Product patent for the second patent family in the SILC project granted in the US
Events after the end of the period
- The rights issue implemented in April was oversubscribed by approximately 30 percent. The company received a capital infusion of approximately SEK 46,9 M after issue expenses
- Our partner NeoTX presented new preclinical data for ANYARA at the AACR Annual Meeting in Chicago
Financial summary
| SEK M | Jan-Mar | Full-year | |||
| 2018 | 2017 | 2017 | |||
| Net sales | 4.8 | 4.7 | 20.2 | ||
| Operating loss | -8.5 | -14.6 | *-102.5 | ||
| Loss after tax | -10.2 | -15.8 | *-108,8 | ||
| Loss per share (SEK) | -0.11 | -0.16 | -1.12 | ||
| Cash and cash equivalents (at close of the period) | 12.8 | 62.7 | 25.2 | ||
* of which write down of property SEK 50 M
For further information, please contact:
| Helén Tuvesson, CEO Tel: +46 (0)46-19 21 56 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 | Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 (0)46-19 20 00 |
The report is also available at https://www.activebiotech.com/en .
Attachment
(0)
(0)Scroll down for more posts ▼